FAST NEWS: Viva Biotech completes Langhua Pharma buyout
The latest: Viva Biotech Holdings (1873.HK) announced Thursday that the acquisition of 20% of Langhua Pharmaceutical by its Weizongchen Pharmaceutical subsidiary for 640 million yuan ($87.6 million) has been completed. Looking…
Cash-strapped Viva Biotech sells stake and plans spinoff
The biotech has gained a capital injection from Temasek and a major Chinese investor, but the deal has not boosted investor confidence Key Takeaways： As well as tapping strategic investors,…
Viva Biotech Dispenses Bitter Pill of Slowing Growth, Asset Devaluation
The contract drug services provider lost roughly 100 million yuan in the first half of this year, as its revenue growth underperformed its peers Key Takeaways: Viva Biotech’s eked out…
FAST NEWS: Viva Biotech Finds First Profits in Drug Research Services
The latest: Viva Biotech Holdings (1873.HK) announced it earned a net profit of 287 million yuan ($45 million) last year, reversing a 386 million yuan loss in 2020, equating to earnings of…
FAST NEWS: Drug Discovery Business Helps Viva Biotech Swing Back to Profit
The latest: Viva Biotech Holdings (1873.HK) released a positive profit forecast, saying it posted a net profit of 300 million yuan ($48.2 million) or more last year, reversing a loss…
Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing
Two key acquisitions last fall helped fuel fivefold rise in first-half revenue, as company swung back into profitability Key Takeaways: Viva Biotech’s fivefold jump in first-half revenues and move back…
Recent Articles
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
HBM gets health boost from drug licensing deals
2142.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
- Sichuan Biokin chases Hong Kong listing after BSM drug deal
-
AI drugs researcher QuantumPharm makes market debut on long road to profit
2228.HK
